REMEGEN announced its performance for the first three quarters, with a net loss attributable to the parent company of approximately 551 million yuan, narrowing by 48.6% year-on-year

RemeGen announced its performance for the first three quarters of 2025, with operating revenue of approximately 1.72 billion yuan, a year-on-year increase of 42.27%; the net loss attributable to the parent company was approximately 551 million yuan, a year-on-year narrowing of 48.6%. The basic loss per share was 1.01 yuan. The reduction in net loss was mainly due to increased product sales revenue, decreased R&D expenses, and a licensing agreement signed with the U.S. company Vor Bio, which led to a reduction in overseas clinical costs